Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 10/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.35 |
| ▸ | BTK | Q06187 | 7/20 | 0.33 |
| ▸ | PIK3R2 | O00459 | 3/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33526211 | 0.89 | BTK (0.37) | PIK3CDPIK3CGPIK3CABTKPIK3CB | |
| SCHEMBL33526235 | 0.88 | KRAS (0.42) | BTK | |
| SCHEMBL33525572 | 0.85 | BTK (0.30) | PIK3CDPIK3CGPIK3CABTK | |
| SCHEMBL33527124 | 0.84 | KRAS (0.43) | PIK3CDBTK | |
| SCHEMBL33526104 | 0.83 | BTK (0.35) | PIK3CDPIK3CGPIK3CABTKLRRK2 | |
| SCHEMBL33525701 | 0.83 | BTK (0.36) | PIK3CDPIK3CGPIK3CABTKLRRK2 | |
| SCHEMBL33525656 | 0.78 | KRAS (0.38) | BTK | |
| SCHEMBL33526366 | 0.77 | BTK (0.39) | BTK | |
| SCHEMBL33525729 | 0.75 | KRAS (0.36) | BTK | |
| SCHEMBL33525563 | 0.74 | BTK (0.38) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | ELI LILLY AND COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260092075-A1 | KRAS INHIBITORS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | KRAS, NRAS, HRAS | PIK3CD 266/4885PIK3CG 358/4885PIK3CA 73/4885 |
| US-20260092075-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | PIK3CD 249/4885PIK3CG 299/4885PIK3CA 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.